Recruiting studies: Egfr Mutation Positive Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Phase 3 · 1 location(s) · Tata Memorial Hospital · NCT05236946 To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Lo
Phase 2 · 7 location(s) · OBI Pharma, Inc · NCT05442060 A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464 A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable
Phase 3 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT04951635 A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC
Phase 2 · 4 location(s) · Guangdong Association of Clinical Trials · NCT07375316 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224 Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT05503667 A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT05104788 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mut
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT04853342 Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
Phase 2 · 1 location(s) · Qingdao Central Hospital · NCT07322783 Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Phase 2 · 2 location(s) · Samsung Medical Center · NCT04591002 Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Phase 2 · 26 location(s) · Sun Yat-sen University · NCT05334277 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366 A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
Phase 1/Phase 2 · 12 location(s) · Wayshine Biopharm, Inc. · NCT06631989 Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy
Phase 2 · 1 location(s) · Konkuk University Medical Center · NCT05469022 Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Phase 2 · 1 location(s) · Samsung Medical Center · NCT05528458 A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT05991193 ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
Phase 2 · 1 location(s) · Fudan University · NCT06775743 A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Trea
Phase 1/Phase 2 · 5 location(s) · Henan Genuine Biotech Co., Ltd. · NCT07231068 Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced
Phase 3 · 166 location(s) · AstraZeneca · NCT06350097 A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Pos
Phase 2 · 34 location(s) · RemeGen Co., Ltd. · NCT06962865 Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR
Phase 2 · 1 location(s) · Peng Zhang · NCT06755684 A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT07058519 Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1
Phase 2 · 2 location(s) · Ruijin Hospital · NCT06269211 The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Phase 1/Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06109558 A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT06970639 A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871 Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Phase 1 · 6 location(s) · Nuvectis Pharma, Inc. · NCT07315113 To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Posi
Phase 2 · 1 location(s) · Juan LI, MD · NCT06192849 Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSC
Phase 2 · 1 location(s) · Shandong Public Health Clinical Center · NCT06709859

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.